{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T19:06:30Z","timestamp":1793214390216,"version":"4.5.0"},"reference-count":37,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jns-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the Neurological Sciences"],"published-print":{"date-parts":[[2024,2]]},"DOI":"10.1016\/j.jns.2024.122866","type":"journal-article","created":{"date-parts":[[2024,1,3]],"date-time":"2024-01-03T15:23:09Z","timestamp":1704295389000},"page":"122866","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["Thyroid hormone dysfunction in MOGAD and other demyelinating diseases"],"prefix":"10.1016","volume":"457","author":[{"given":"Ariel","family":"Rechtman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Omri","family":"Zveik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nitsan","family":"Haham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tal","family":"Freidman-Korn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adi","family":"Vaknin-Dembinsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jns.2024.122866_bb0005","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.2214\/AJR.20.24061","article-title":"MOGAD: how it differs from and resembles other Neuroinflammatory disorders","volume":"216","author":"Shahriari","year":"2021","journal-title":"Am. J. Roentgenol."},{"key":"10.1016\/j.jns.2024.122866_bb0010","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2022.103932","article-title":"Multiple sclerosis incidence: a systematic review of change over time by geographical region","volume":"63","author":"Lane","year":"2022","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.jns.2024.122866_bb0015","doi-asserted-by":"crossref","DOI":"10.1111\/cei.12733","article-title":"Prediction of disease severity in neuromyelitis optica by the levels of interleukin (IL)-6 produced during remission phase","author":"Barros","year":"2016","journal-title":"Clin. Exp. Immunol."},{"key":"10.1016\/j.jns.2024.122866_bb0020","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1136\/jnnp-2020-323158","article-title":"Prevalence and incidence of neuromyelitis optica spectrum disorder, aquaporin-4 antibody-positive NMOSD and MOG antibody-positive disease in Oxfordshire, UK","volume":"91","author":"O\u2019Connell","year":"2020","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.jns.2024.122866_bb0025","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2022.885218","article-title":"Myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD): a review of clinical and MRI features, diagnosis, and management","volume":"13","author":"Sechi","year":"2022","journal-title":"Front. Neurol."},{"key":"10.1016\/j.jns.2024.122866_bb0030","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1046\/j.1471-4159.1999.0720001.x","article-title":"The structure and function of myelin oligodendrocyte glycoprotein","volume":"72","author":"Johns","year":"1999","journal-title":"J. Neurochem."},{"key":"10.1016\/j.jns.2024.122866_bb0035","series-title":"Vitamins & Hormones","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/S0083-6729(05)71004-9","article-title":"Thyroid hormones and brain development","volume":"71","author":"Bernal","year":"2005"},{"key":"10.1016\/j.jns.2024.122866_bb0040","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.3389\/fneur.2019.01103","article-title":"Thyroid hormones in the brain and their impact in recovery mechanisms after stroke","volume":"10","author":"Talhada","year":"2019","journal-title":"Front. Neurol."},{"key":"10.1016\/j.jns.2024.122866_bb0045","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1002\/glia.24165","article-title":"Cerebrospinal fluid of progressive multiple sclerosis patients reduces differentiation and immune functions of oligodendrocyte progenitor cells","volume":"70","author":"Zveik","year":"2022","journal-title":"Glia"},{"key":"10.1016\/j.jns.2024.122866_bb0050","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.autrev.2014.10.016","article-title":"Autoimmune thyroid disorders","volume":"14","author":"Antonelli","year":"2015","journal-title":"Autoimmun. Rev."},{"key":"10.1016\/j.jns.2024.122866_bb0055","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1136\/ard.2004.022624","article-title":"Presence of systemic autoimmune disorders in patients with autoimmune thyroid diseases","volume":"63","author":"Tektonidou","year":"2004","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.jns.2024.122866_bb0060","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.beem.2004.11.004","article-title":"Non-thyroid autoantibodies in autoimmune thyroid disease","volume":"19","author":"Weetman","year":"2005","journal-title":"Best Pract. Res. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.jns.2024.122866_bb0065","doi-asserted-by":"crossref","first-page":"362","DOI":"10.3109\/08916934.2015.1030614","article-title":"Complicating autoimmune diseases in myasthenia gravis: a review","volume":"48","author":"Nacu","year":"2015","journal-title":"Autoimmunity"},{"key":"10.1016\/j.jns.2024.122866_bb0070","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1212\/WNL.53.4.883","article-title":"Association of MS with thyroid disorders","volume":"53","author":"Karni","year":"1999","journal-title":"Neurology"},{"key":"10.1016\/j.jns.2024.122866_bb0075","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/1740-2557-2-9","article-title":"Co-occurrence of autoimmune thyroid disease in a multiple sclerosis cohort","volume":"2","author":"Sloka","year":"2005","journal-title":"J. Autoimmune Dis."},{"key":"10.1016\/j.jns.2024.122866_bb0080","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/s43162-020-00017-w","article-title":"The pattern of thyroiditis in multiple sclerosis: a cross-sectional study in a tertiary care hospital in Egypt","volume":"32","author":"Rashad","year":"2020","journal-title":"Egypt. J. Intern. Med."},{"key":"10.1016\/j.jns.2024.122866_bb0085","doi-asserted-by":"crossref","first-page":"311","DOI":"10.3389\/fimmu.2018.00311","article-title":"The footprints of poly-autoimmunity: evidence for common biological factors involved in multiple sclerosis and Hashimoto\u2019s thyroiditis","volume":"9","author":"Perga","year":"2018","journal-title":"Front. Immunol."},{"key":"10.1016\/j.jns.2024.122866_bb0090","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1186\/s12883-019-1560-7","article-title":"Free thyroxine level is associated with both relapse rate and poor neurofunction in first-attack Neuromyelitis Optica Spectrum disorder (NMOSD) patients","volume":"19","author":"He","year":"2019","journal-title":"BMC Neurol."},{"key":"10.1016\/j.jns.2024.122866_bb0095","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/j.jns.2016.09.039","article-title":"Low T3 syndrome in neuromyelitis optica spectrum disorder: associations with disease activity and disability","volume":"370","author":"Cho","year":"2016","journal-title":"J. Neurol. Sci."},{"key":"10.1016\/j.jns.2024.122866_bb0100","doi-asserted-by":"crossref","first-page":"546","DOI":"10.4103\/1735-5362.245966","article-title":"Effects of thyroid-stimulating hormone on adhesion molecules and pro-inflammatory cytokines secretion in human umbilical vein endothelial cells","volume":"13","author":"Milani","year":"2018","journal-title":"Res. Pharm. Sci."},{"key":"10.1016\/j.jns.2024.122866_bb0105","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1002\/ana.1032","article-title":"Recommended diagnostic criteria for multiple sclerosis: guidelines from the international panel on the diagnosis of multiple sclerosis","volume":"50","author":"McDonald","year":"2001","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.jns.2024.122866_bb0110","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1212\/WNL.0000000000001729","article-title":"International consensus diagnostic criteria for neuromyelitis optica spectrum disorders","volume":"85","author":"Wingerchuk","year":"2015","journal-title":"Neurology"},{"key":"10.1016\/j.jns.2024.122866_bb0115","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/S1474-4422(22)00431-8","article-title":"Diagnosis of myelin oligodendrocyte glycoprotein antibody-associated disease: international MOGAD panel proposed criteria","volume":"22","author":"Banwell","year":"2023","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.jns.2024.122866_bb0120","series-title":"STATEMENT standardized MR imaging protocol for multiple sclerosis: consortium of MS centers consensus","volume":"455\u2013461","author":"Li","year":"2006"},{"key":"10.1016\/j.jns.2024.122866_bb0125","first-page":"1","article-title":"Volumetric brain loss correlates with a relapsing MOGAD disease course","volume":"13","author":"Rechtman","year":"2022"},{"key":"10.1016\/j.jns.2024.122866_bb0130","doi-asserted-by":"crossref","first-page":"81","DOI":"10.2147\/PTT.S186637","article-title":"A narrative review of psoriasis and multiple sclerosis: links and risks","volume":"9","author":"Silfvast-Kaiser","year":"2019","journal-title":"Psoriasis Targets Ther."},{"key":"10.1016\/j.jns.2024.122866_bb0135","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1177\/1352458514564490","article-title":"A systematic review of the incidence and prevalence of autoimmune disease in multiple sclerosis","volume":"21","author":"Marrie","year":"2015","journal-title":"Mult. Scler. J."},{"key":"10.1016\/j.jns.2024.122866_bb0140","article-title":"Burden and cost of comorbidities in patients with neuromyelitis optica spectrum disorder","volume":"427","author":"Exuzides","year":"2021","journal-title":"J. Neurol. Sci."},{"key":"10.1016\/j.jns.2024.122866_bb0145","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1136\/jnnp-2011-300403","article-title":"Clinical features of neuromyelitis optica in a large Japanese cohort: comparison between phenotypes","volume":"82","author":"Nagaishi","year":"2011","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.jns.2024.122866_bb0150","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1016\/j.msard.2018.11.008","article-title":"Autoimmune diseases associated with Neuromyelitis Optica Spectrum disorders: a literature review","volume":"27","author":"Shahmohammadi","year":"2019","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.jns.2024.122866_bb0155","article-title":"Autoimmune diseases and cancers overlapping with myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD): a systematic review","volume":"8","author":"Molazadeh","year":"2022","journal-title":"Mult. Scler. J. - Exp. Transl. Clin."},{"key":"10.1016\/j.jns.2024.122866_bb0160","first-page":"1695","article-title":"Association between serum interleukin-6 and serum 3,5,3\u2032-triiodothyronine in nonthyroidal illness","volume":"77","author":"Boelen","year":"1993","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.jns.2024.122866_bb0165","doi-asserted-by":"crossref","DOI":"10.1016\/j.jneuroim.2022.577925","article-title":"IL-6 as a marker for NMOSD disease activity","volume":"370","author":"Haramati","year":"2022","journal-title":"J. Neuroimmunol."},{"key":"10.1016\/j.jns.2024.122866_bb0170","doi-asserted-by":"crossref","first-page":"R65","DOI":"10.1530\/EJE-21-1171","article-title":"The interplay of thyroid hormones and the immune system \u2013 where we stand and why we need to know about it","volume":"186","author":"Wenzek","year":"2022","journal-title":"Eur. J. Endocrinol."},{"key":"10.1016\/j.jns.2024.122866_bb0175","doi-asserted-by":"crossref","first-page":"350","DOI":"10.3389\/fendo.2019.00350","article-title":"Thyroid hormone action on innate immunity","volume":"10","author":"Montesinos","year":"2019","journal-title":"Front. Endocrinol."},{"key":"10.1016\/j.jns.2024.122866_bb0180","author":"Liu"},{"key":"10.1016\/j.jns.2024.122866_bb0185","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2012\/351864","article-title":"TSH and thyrotropic agonists: key actors in thyroid homeostasis","volume":"2012","author":"Dietrich","year":"2012","journal-title":"J. Thyroid. Res."}],"container-title":["Journal of the Neurological Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022510X24000017?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022510X24000017?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,20]],"date-time":"2025-09-20T16:05:42Z","timestamp":1758384342000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022510X24000017"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2]]},"references-count":37,"alternative-id":["S0022510X24000017"],"URL":"https:\/\/doi.org\/10.1016\/j.jns.2024.122866","relation":{},"ISSN":["0022-510X"],"issn-type":[{"value":"0022-510X","type":"print"}],"subject":[],"published":{"date-parts":[[2024,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Thyroid hormone dysfunction in MOGAD and other demyelinating diseases","name":"articletitle","label":"Article Title"},{"value":"Journal of the Neurological Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jns.2024.122866","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"122866"}}